25 XP   0   0   10

Cytosorbents Crp
Buy, Hold or Sell?

Let's analyse Cytosorbents together

PenkeI guess you are interested in Cytosorbents Crp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cytosorbents Crp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cytosorbents Crp

I send you an email if I find something interesting about Cytosorbents Crp.

Quick analysis of Cytosorbents (30 sec.)










What can you expect buying and holding a share of Cytosorbents? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$0.43
Expected worth in 1 year
$0.21
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-0.22
Return On Investment
-25.7%

For what price can you sell your share?

Current Price per Share
$0.87
Expected price per share
$0.86 - $1.05
How sure are you?
50%

1. Valuation of Cytosorbents (5 min.)




Live pricePrice per Share (EOD)

$0.87

Intrinsic Value Per Share

$-7.96 - $-3.95

Total Value Per Share

$-7.54 - $-3.52

2. Growth of Cytosorbents (5 min.)




Is Cytosorbents growing?

Current yearPrevious yearGrowGrow %
How rich?$23.2m$44.3m-$20.6m-87.2%

How much money is Cytosorbents making?

Current yearPrevious yearGrowGrow %
Making money-$6.9m-$8.1m$1.1m17.2%
Net Profit Margin-86.9%-114.8%--

How much money comes from the company's main activities?

3. Financial Health of Cytosorbents (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#206 / 340

Most Revenue
#205 / 340

Most Profit
#238 / 340

Most Efficient
#237 / 340

What can you expect buying and holding a share of Cytosorbents? (5 min.)

Welcome investor! Cytosorbents's management wants to use your money to grow the business. In return you get a share of Cytosorbents.

What can you expect buying and holding a share of Cytosorbents?

First you should know what it really means to hold a share of Cytosorbents. And how you can make/lose money.

Speculation

The Price per Share of Cytosorbents is $0.8668. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cytosorbents.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cytosorbents, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.43. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cytosorbents.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.11-12.4%-0.13-15.1%-0.15-17.4%-0.10-12.0%-0.08-9.5%
Usd Book Value Change Per Share0.0910.1%-0.06-6.4%-0.13-14.5%0.010.7%0.022.0%
Usd Dividend Per Share0.000.0%0.000.0%0.022.7%0.000.5%0.000.5%
Usd Total Gains Per Share0.0910.1%-0.06-6.4%-0.10-11.8%0.011.2%0.022.5%
Usd Price Per Share1.11-2.49-2.07-5.17-5.66-
Price to Earnings Ratio-2.58--4.88--9.13--28.24--19.62-
Price-to-Total Gains Ratio12.65--18.56-5.03--61.77--50.84-
Price to Book Ratio2.59-5.63-2.47-13.34-9.00-
Price-to-Total Gains Ratio12.65--18.56-5.03--61.77--50.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.8668
Number of shares1153
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.060.01
Usd Total Gains Per Share-0.060.01
Gains per Quarter (1153 shares)-64.2412.04
Gains per Year (1153 shares)-256.9648.17
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-257-267212738
20-514-524425486
30-771-7816481134
40-1028-103885108182
50-1285-1295106135230
60-1542-1552127162278
70-1799-1809149189326
80-2056-2066170215374
90-2313-2323191242422
100-2570-2580212269470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%3.037.00.07.5%3.074.00.03.9%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%4.016.00.020.0%13.027.00.032.5%24.049.04.031.2%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%5.00.035.012.5%14.00.063.018.2%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%14.026.00.035.0%27.047.03.035.1%

Fundamentals of Cytosorbents

About Cytosorbents Crp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Fundamental data was last updated by Penke on 2024-04-11 05:25:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cytosorbents Crp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cytosorbents earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cytosorbents to the Medical Devices industry mean.
  • A Net Profit Margin of -67.3% means that $-0.67 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cytosorbents Crp:

  • The MRQ is -67.3%. The company is making a huge loss. -2
  • The TTM is -86.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-67.3%TTM-86.9%+19.6%
TTM-86.9%YOY-114.8%+27.9%
TTM-86.9%5Y-74.5%-12.4%
5Y-74.5%10Y-116.8%+42.3%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-67.3%-11.2%-56.1%
TTM-86.9%-19.6%-67.3%
YOY-114.8%-14.4%-100.4%
5Y-74.5%-21.3%-53.2%
10Y-116.8%-24.8%-92.0%
1.1.2. Return on Assets

Shows how efficient Cytosorbents is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cytosorbents to the Medical Devices industry mean.
  • -11.0% Return on Assets means that Cytosorbents generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cytosorbents Crp:

  • The MRQ is -11.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.0%TTM-13.4%+2.5%
TTM-13.4%YOY-11.7%-1.8%
TTM-13.4%5Y-10.4%-3.0%
5Y-10.4%10Y-14.4%+4.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.0%-4.0%-7.0%
TTM-13.4%-4.5%-8.9%
YOY-11.7%-4.8%-6.9%
5Y-10.4%-4.0%-6.4%
10Y-14.4%-5.2%-9.2%
1.1.3. Return on Equity

Shows how efficient Cytosorbents is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cytosorbents to the Medical Devices industry mean.
  • -25.1% Return on Equity means Cytosorbents generated $-0.25 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cytosorbents Crp:

  • The MRQ is -25.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -30.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.1%TTM-30.9%+5.8%
TTM-30.9%YOY-18.1%-12.9%
TTM-30.9%5Y-27.1%-3.8%
5Y-27.1%10Y-30.5%+3.4%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.1%-3.9%-21.2%
TTM-30.9%-5.6%-25.3%
YOY-18.1%-5.9%-12.2%
5Y-27.1%-6.1%-21.0%
10Y-30.5%-7.1%-23.4%

1.2. Operating Efficiency of Cytosorbents Crp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cytosorbents is operating .

  • Measures how much profit Cytosorbents makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cytosorbents to the Medical Devices industry mean.
  • An Operating Margin of -105.7% means the company generated $-1.06  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cytosorbents Crp:

  • The MRQ is -105.7%. The company is operating very inefficient. -2
  • The TTM is -98.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-105.7%TTM-98.2%-7.5%
TTM-98.2%YOY-108.8%+10.6%
TTM-98.2%5Y-74.5%-23.6%
5Y-74.5%10Y-114.2%+39.7%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-105.7%-21.4%-84.3%
TTM-98.2%-18.0%-80.2%
YOY-108.8%-13.7%-95.1%
5Y-74.5%-19.2%-55.3%
10Y-114.2%-24.0%-90.2%
1.2.2. Operating Ratio

Measures how efficient Cytosorbents is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 2.06 means that the operating costs are $2.06 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cytosorbents Crp:

  • The MRQ is 2.057. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.954. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.057TTM1.954+0.103
TTM1.954YOY2.088-0.134
TTM1.9545Y1.745+0.209
5Y1.74510Y2.151-0.406
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0571.428+0.629
TTM1.9541.433+0.521
YOY2.0881.431+0.657
5Y1.7451.440+0.305
10Y2.1511.382+0.769

1.3. Liquidity of Cytosorbents Crp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cytosorbents is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 1.77 means the company has $1.77 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cytosorbents Crp:

  • The MRQ is 1.767. The company is able to pay all its short-term debts. +1
  • The TTM is 2.090. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.767TTM2.090-0.323
TTM2.090YOY3.607-1.517
TTM2.0905Y4.021-1.931
5Y4.02110Y3.859+0.162
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7672.787-1.020
TTM2.0902.763-0.673
YOY3.6073.488+0.119
5Y4.0213.617+0.404
10Y3.8593.537+0.322
1.3.2. Quick Ratio

Measures if Cytosorbents is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cytosorbents to the Medical Devices industry mean.
  • A Quick Ratio of 1.39 means the company can pay off $1.39 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cytosorbents Crp:

  • The MRQ is 1.388. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.727. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.388TTM1.727-0.339
TTM1.727YOY3.044-1.317
TTM1.7275Y3.580-1.853
5Y3.58010Y3.793-0.213
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3881.539-0.151
TTM1.7271.656+0.071
YOY3.0442.113+0.931
5Y3.5802.289+1.291
10Y3.7932.256+1.537

1.4. Solvency of Cytosorbents Crp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cytosorbents assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cytosorbents to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.56 means that Cytosorbents assets are financed with 56.3% credit (debt) and the remaining percentage (100% - 56.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cytosorbents Crp:

  • The MRQ is 0.563. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.553. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.563TTM0.553+0.010
TTM0.553YOY0.370+0.183
TTM0.5535Y0.437+0.116
5Y0.43710Y0.590-0.154
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5630.389+0.174
TTM0.5530.386+0.167
YOY0.3700.347+0.023
5Y0.4370.442-0.005
10Y0.5900.460+0.130
1.4.2. Debt to Equity Ratio

Measures if Cytosorbents is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cytosorbents to the Medical Devices industry mean.
  • A Debt to Equity ratio of 128.8% means that company has $1.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cytosorbents Crp:

  • The MRQ is 1.288. The company is able to pay all its debts with equity. +1
  • The TTM is 1.255. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.288TTM1.255+0.033
TTM1.255YOY0.594+0.660
TTM1.2555Y1.198+0.057
5Y1.19810Y1.101+0.097
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2880.559+0.729
TTM1.2550.560+0.695
YOY0.5940.478+0.116
5Y1.1980.624+0.574
10Y1.1010.674+0.427

2. Market Valuation of Cytosorbents Crp

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cytosorbents generates.

  • Above 15 is considered overpriced but always compare Cytosorbents to the Medical Devices industry mean.
  • A PE ratio of -2.58 means the investor is paying $-2.58 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cytosorbents Crp:

  • The EOD is -2.016. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.582. Based on the earnings, the company is expensive. -2
  • The TTM is -4.880. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.016MRQ-2.582+0.566
MRQ-2.582TTM-4.880+2.298
TTM-4.880YOY-9.134+4.254
TTM-4.8805Y-28.241+23.361
5Y-28.24110Y-19.623-8.618
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-2.016-1.067-0.949
MRQ-2.582-1.578-1.004
TTM-4.880-2.341-2.539
YOY-9.134-2.969-6.165
5Y-28.241-2.081-26.160
10Y-19.623-1.463-18.160
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cytosorbents Crp:

  • The EOD is -1.798. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.303. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.571. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.798MRQ-2.303+0.504
MRQ-2.303TTM-6.571+4.269
TTM-6.571YOY-3.359-3.213
TTM-6.5715Y-13.008+6.436
5Y-13.00810Y-25.073+12.065
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-1.798-1.015-0.783
MRQ-2.303-1.544-0.759
TTM-6.571-2.914-3.657
YOY-3.359-6.192+2.833
5Y-13.008-4.771-8.237
10Y-25.073-5.214-19.859
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cytosorbents is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 2.59 means the investor is paying $2.59 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cytosorbents Crp:

  • The EOD is 2.022. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.589. Based on the equity, the company is underpriced. +1
  • The TTM is 5.628. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.022MRQ2.589-0.567
MRQ2.589TTM5.628-3.039
TTM5.628YOY2.473+3.155
TTM5.6285Y13.336-7.708
5Y13.33610Y9.005+4.331
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD2.0222.021+0.001
MRQ2.5892.379+0.210
TTM5.6282.465+3.163
YOY2.4733.219-0.746
5Y13.3363.798+9.538
10Y9.0054.163+4.842
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cytosorbents Crp.

3.1. Institutions holding Cytosorbents Crp

Institutions are holding 39.535% of the shares of Cytosorbents Crp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Granahan Investment Management Inc..6.6640.132736181432065750133.0688
2023-12-31Skylands Capital, LLC5.99370.5317325421330954310.512
2023-09-30Avenir Corporation5.0050.47822717397-2335-0.0859
2023-12-31Vanguard Group Inc3.59080.0001194955100
2023-12-31Neuberger Berman Group LLC3.31860.0017180179929910319.9044
2023-12-31Sargent Investment Group, LLC2.41050.31821308747516994.1127
2023-12-31BlackRock Inc1.33780726320-444-0.0611
2023-12-31CM Management, LLC0.76440.3702415000-35000-7.7778
2023-12-31Geode Capital Management, LLC0.6721036492000
2023-09-30Jacob Asset Mgmt Of NY LLC0.36460.5248197940-40000-16.811
2023-12-31Renaissance Technologies Corp0.32290.00031753205622047.204
2023-12-31Atlantic Trust Group, LLC0.3180.00041726495000040.7667
2023-12-31State Street Corporation0.2783015109300
2023-12-31Morgan Stanley - Brokerage Accounts0.2210119978-3330-2.7006
2023-12-31Advisor Group Holdings, Inc.0.20760.0002112710-72572-39.1684
2023-12-31Northern Trust Corp0.1382075013-2-0.0027
2023-12-31Bank of America Corp0.123066780-1134-1.6698
2023-12-31Raymond James Finl Svs Advisors, Inc.0.11160.000160591-1340-2.1637
2023-12-31Dimensional Fund Advisors, Inc.0.1042056570-22888-28.8052
2023-12-31Raymond James & Associates0.0921050000500000
Total 32.03842.358617394734+2703270+15.5%

3.2. Funds holding Cytosorbents Crp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.39850.0001130221600
2023-12-31JNL Multi-Manager Small Cap Growth A2.15320.0557116905157389796.4283
2024-02-29Neuberger Berman Intrinsic Value I1.66120.0569901950-9536-1.0462
2023-12-31M&G (ACS) Granahan US Sm Cp Gr GBPZ1AAcc1.59370.2204865274504726139.9886
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.04660.000556823300
2023-12-31Granahan Inv Mgt Sm-Cap Core Gr0.86770.219471085286190154.7851
2023-12-31Victory Small Cap Stock0.86770.0521471085286190154.7851
2024-02-29Fidelity Extended Market Index0.3910.0005212311-1029-0.4823
2023-12-31Perinvest(Lux) Sicav Harbour US Eq A0.27630.37150000-55000-26.8293
2023-12-31Neuberger Berman Small Cap Intrinsic Val0.24590.041413348813327361987.4419
2023-12-31Granahan Inv Mgt Small Cap Discoveries0.23510.4386127632108642572.1011
2023-09-30BlackRock Extended Mkt Composite0.21850.001611862300
2024-03-31BlackRock Extended Equity Market K0.19070.0007103526370.0358
2023-12-31Neuberger Berman US SCp Intrs Val $I Acc0.1760.0339553740294.4029
2024-03-28iShares Micro-Cap ETF0.1620.00918796000
2024-02-29Fidelity Total Market Index0.11530.00016258600
2024-02-29Fidelity Series Total Market Index0.09150.00014967800
2023-12-31Acuitas US Microcap Institutional0.08380.07384550226512139.6103
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06840.00073712500
2024-02-29Vanguard Balanced Index Inv0.06560.00013564100
Total 12.90871.57447008503+1857931+26.5%

3.3. Insider Transactions

Insiders are holding 9.173% of the shares of Cytosorbents Crp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-13Alan D SobelBUY225571.33
2023-08-07Michael G BatorBUY20003.17
2023-08-04Michael G BatorBUY10003.23
2023-05-25Kathleen P BlochBUY33002.85
2023-05-10Kathleen P BlochBUY100003.11

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cytosorbents Crp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.088-0.056+164%-0.125+243%0.006+1402%0.017+408%
Book Value Per Share--0.4290.437-2%0.817-48%0.736-42%0.426+1%
Current Ratio--1.7672.090-15%3.607-51%4.021-56%3.859-54%
Debt To Asset Ratio--0.5630.553+2%0.370+52%0.437+29%0.590-5%
Debt To Equity Ratio--1.2881.255+3%0.594+117%1.198+8%1.101+17%
Dividend Per Share----0%0.023-100%0.005-100%0.004-100%
Eps---0.107-0.131+22%-0.151+41%-0.104-3%-0.082-23%
Free Cash Flow Per Share---0.121-0.104-14%-0.160+33%-0.093-23%-0.067-44%
Free Cash Flow To Equity Per Share--0.104-0.037+136%-0.137+231%-0.006+106%0.006+1595%
Gross Profit Margin--0.7750.947-18%1.079-28%1.005-23%1.003-23%
Intrinsic Value_10Y_max---3.949--------
Intrinsic Value_10Y_min---7.964--------
Intrinsic Value_1Y_max---0.287--------
Intrinsic Value_1Y_min---0.524--------
Intrinsic Value_3Y_max---0.945--------
Intrinsic Value_3Y_min---1.820--------
Intrinsic Value_5Y_max---1.703--------
Intrinsic Value_5Y_min---3.378--------
Market Cap47061692.480-28%60265896.000135055330.000-55%112523486.000-46%280738632.200-79%307474022.446-80%
Net Profit Margin---0.673-0.869+29%-1.148+71%-0.745+11%-1.168+74%
Operating Margin---1.057-0.982-7%-1.088+3%-0.745-29%-1.142+8%
Operating Ratio--2.0571.954+5%2.088-1%1.745+18%2.151-4%
Pb Ratio2.022-28%2.5895.628-54%2.473+5%13.336-81%9.005-71%
Pe Ratio-2.016+22%-2.582-4.880+89%-9.134+254%-28.241+994%-19.623+660%
Price Per Share0.867-28%1.1102.488-55%2.073-46%5.171-79%5.663-80%
Price To Free Cash Flow Ratio-1.798+22%-2.303-6.571+185%-3.359+46%-13.008+465%-25.073+989%
Price To Total Gains Ratio9.880-28%12.652-18.559+247%5.030+152%-61.773+588%-50.845+502%
Quick Ratio--1.3881.727-20%3.044-54%3.580-61%3.793-63%
Return On Assets---0.110-0.134+23%-0.117+7%-0.104-5%-0.144+32%
Return On Equity---0.251-0.309+23%-0.181-28%-0.271+8%-0.305+22%
Total Gains Per Share--0.088-0.056+164%-0.102+217%0.010+740%0.021+313%
Usd Book Value--23275163.00023709214.750-2%44376069.250-48%39948434.900-42%23115228.925+1%
Usd Book Value Change Per Share--0.088-0.056+164%-0.125+243%0.006+1402%0.017+408%
Usd Book Value Per Share--0.4290.437-2%0.817-48%0.736-42%0.426+1%
Usd Dividend Per Share----0%0.023-100%0.005-100%0.004-100%
Usd Eps---0.107-0.131+22%-0.151+41%-0.104-3%-0.082-23%
Usd Free Cash Flow---6543333.000-5630552.250-14%-8672464.500+33%-5053366.500-23%-3639337.400-44%
Usd Free Cash Flow Per Share---0.121-0.104-14%-0.160+33%-0.093-23%-0.067-44%
Usd Free Cash Flow To Equity Per Share--0.104-0.037+136%-0.137+231%-0.006+106%0.006+1595%
Usd Market Cap47061692.480-28%60265896.000135055330.000-55%112523486.000-46%280738632.200-79%307474022.446-80%
Usd Price Per Share0.867-28%1.1102.488-55%2.073-46%5.171-79%5.663-80%
Usd Profit---5834907.000-6985247.750+20%-8183434.500+40%-5616831.450-4%-4165894.625-29%
Usd Revenue--8668215.0008101156.750+7%7339977.500+18%8204575.500+6%5328302.625+63%
Usd Total Gains Per Share--0.088-0.056+164%-0.102+217%0.010+740%0.021+313%
 EOD+2 -6MRQTTM+16 -18YOY+19 -175Y+12 -2410Y+19 -17

4.2. Fundamental Score

Let's check the fundamental score of Cytosorbents Crp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.016
Price to Book Ratio (EOD)Between0-12.022
Net Profit Margin (MRQ)Greater than0-0.673
Operating Margin (MRQ)Greater than0-1.057
Quick Ratio (MRQ)Greater than11.388
Current Ratio (MRQ)Greater than11.767
Debt to Asset Ratio (MRQ)Less than10.563
Debt to Equity Ratio (MRQ)Less than11.288
Return on Equity (MRQ)Greater than0.15-0.251
Return on Assets (MRQ)Greater than0.05-0.110
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Cytosorbents Crp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.830
Ma 20Greater thanMa 500.923
Ma 50Greater thanMa 1000.965
Ma 100Greater thanMa 2001.097
OpenGreater thanClose0.880
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Long-term Assets Other  1,7342,7114,446-1684,278-1294,149-7,802-3,654



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets53,261
Total Liabilities29,985
Total Stockholder Equity23,275
 As reported
Total Liabilities 29,985
Total Stockholder Equity+ 23,275
Total Assets = 53,261

Assets

Total Assets53,261
Total Current Assets25,703
Long-term Assets27,558
Total Current Assets
Cash And Cash Equivalents 14,131
Net Receivables 6,057
Inventory 3,680
Other Current Assets 1,834
Total Current Assets  (as reported)25,703
Total Current Assets  (calculated)25,703
+/-0
Long-term Assets
Property Plant Equipment 22,115
Intangible Assets 3,907
Long-term Assets  (as reported)27,558
Long-term Assets  (calculated)26,022
+/- 1,536

Liabilities & Shareholders' Equity

Total Current Liabilities14,546
Long-term Liabilities15,440
Total Stockholder Equity23,275
Total Current Liabilities
Short-term Debt 2,874
Short Long Term Debt 2,500
Accounts payable 3,802
Other Current Liabilities 6,489
Total Current Liabilities  (as reported)14,546
Total Current Liabilities  (calculated)15,665
+/- 1,119
Long-term Liabilities
Long term Debt 2,543
Capital Lease Obligations 13,270
Long-term Liabilities  (as reported)15,440
Long-term Liabilities  (calculated)15,813
+/- 374
Total Stockholder Equity
Common Stock54
Retained Earnings -282,505
Accumulated Other Comprehensive Income 529
Other Stockholders Equity 305,197
Total Stockholder Equity (as reported)23,275
Total Stockholder Equity (calculated)23,275
+/-0
Other
Capital Stock54
Cash and Short Term Investments 14,131
Common Stock Shares Outstanding 48,624
Current Deferred Revenue1,381
Liabilities and Stockholders Equity 53,261
Net Debt 4,182
Net Invested Capital 28,318
Net Working Capital 11,157
Property Plant and Equipment Gross 25,151
Short Long Term Debt Total 18,313



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-31
> Total Assets 
46
30
30
20
19
17
5,577
4,173
3,445
2,754
2,019
1,326
803
803
4,145
3,878
3,387
3,387
1,789
1,288
2,238
2,238
953
1,110
1,812
2,875
3,862
2,934
2,123
2,784
2,896
3,268
3,339
3,339
2,981
4,039
4,046
12,393
11,257
9,627
8,469
15,864
14,099
12,802
11,254
9,512
12,711
10,858
9,694
8,289
22,086
22,218
24,103
28,303
34,946
34,249
32,747
30,995
28,483
28,682
27,383
44,226
49,259
104,282
89,950
87,479
98,193
95,067
89,519
83,272
71,205
62,270
63,232
57,463
52,445
47,575
53,261
53,26147,57552,44557,46363,23262,27071,20583,27289,51995,06798,19387,47989,950104,28249,25944,22627,38328,68228,48330,99532,74734,24934,94628,30324,10322,21822,0868,2899,69410,85812,7119,51211,25412,80214,09915,8648,4699,62711,25712,3934,0464,0392,9813,3393,3393,2682,8962,7842,1232,9343,8622,8751,8121,1109532,2382,2381,2881,7893,3873,3873,8784,1458038031,3262,0192,7543,4454,1735,577171920303046
   > Total Current Assets 
30
20
10
7
5
4
4,969
3,619
2,898
2,223
1,535
890
412
412
3,767
3,529
3,066
3,066
1,490
1,001
1,965
1,965
675
829
1,400
2,471
3,452
2,516
1,697
2,358
2,467
2,855
2,940
2,940
2,587
3,644
3,487
11,828
10,622
8,954
7,607
14,882
13,041
11,591
9,860
8,041
11,074
9,053
7,828
6,281
19,741
19,386
20,739
24,515
30,780
29,950
28,264
24,828
22,214
22,351
20,902
37,529
41,948
96,802
82,453
79,635
77,085
72,752
64,299
55,854
41,647
32,381
33,760
28,165
23,644
19,261
25,703
25,70319,26123,64428,16533,76032,38141,64755,85464,29972,75277,08579,63582,45396,80241,94837,52920,90222,35122,21424,82828,26429,95030,78024,51520,73919,38619,7416,2817,8289,05311,0748,0419,86011,59113,04114,8827,6078,95410,62211,8283,4873,6442,5872,9402,9402,8552,4672,3581,6972,5163,4522,4711,4008296751,9651,9651,0011,4903,0663,0663,5293,7674124128901,5352,2232,8983,6194,969457102030
       Cash And Cash Equivalents 
28
10
10
4
4
2
4,859
3,577
2,873
2,190
1,466
775
212
212
3,594
3,375
2,749
2,749
1,424
937
1,596
1,596
596
758
1,056
2,436
3,417
2,296
1,187
1,803
1,742
2,061
1,729
1,729
1,871
2,350
2,183
6,416
4,878
433
3,605
10,419
8,017
7,386
5,317
3,537
8,670
6,375
5,245
3,240
16,402
15,400
17,322
21,090
25,283
24,911
22,369
19,647
16,342
15,978
12,232
26,389
35,114
87,978
71,422
68,468
65,609
61,043
52,138
43,023
30,164
22,552
22,145
19,048
13,152
8,359
14,131
14,1318,35913,15219,04822,14522,55230,16443,02352,13861,04365,60968,46871,42287,97835,11426,38912,23215,97816,34219,64722,36924,91125,28321,09017,32215,40016,4023,2405,2456,3758,6703,5375,3177,3868,01710,4193,6054334,8786,4162,1832,3501,8711,7291,7292,0611,7421,8031,1872,2963,4172,4361,0567585961,5961,5969371,4242,7492,7493,3753,5942122127751,4662,1902,8733,5774,859244101028
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
200
200
0
0
0
200
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,745
4,745
7,347
1,945
2,939
3,188
1,943
2,192
2,490
249
0
2,192
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000002,19202492,4902,1921,9433,1882,9391,9457,3474,7454,7450000000000000002000002002000000000000000000
       Net Receivables 
2
2
3
3
1
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36
40
43
52
52
52
84
194
453
327
330
562
819
673
501
553
649
760
945
1,406
1,433
1,732
2,059
2,350
2,206
2,352
2,903
3,643
3,943
3,267
3,450
3,448
4,467
5,395
3,890
5,797
5,159
5,019
5,755
5,241
4,523
4,577
5,171
4,961
5,665
5,528
7,025
6,179
6,057
6,0576,1797,0255,5285,6654,9615,1714,5774,5235,2415,7555,0195,1595,7973,8905,3954,4673,4483,4503,2673,9433,6432,9032,3522,2062,3502,0591,7321,4331,406945760649553501673819562330327453194845252524340360000000000000000000000213322
       Other Current Assets 
0
10
0
0
0
0
110
42
25
33
69
115
0
201
173
154
0
117
66
64
370
369
79
71
345
34
36
34
44
47
146
116
476
476
156
738
605
193
365
225
700
148
275
372
512
194
162
220
316
451
390
546
416
393
1,826
617
1,119
700
960
1,157
2,088
3,778
957
1,002
3,198
3,040
2,032
1,940
2,872
2,809
1,331
1,326
2,489
1,863
1,422
1,746
1,834
1,8341,7461,4221,8632,4891,3261,3312,8092,8721,9402,0323,0403,1981,0029573,7782,0881,1579607001,1196171,82639341654639045131622016219451237227514870022536519360573815647647611614647443436343457179369370646611701541732010115693325421100000100
   > Long-term Assets 
0
10
20
13
14
13
609
554
547
531
484
436
0
390
378
349
0
321
299
286
0
274
278
281
412
405
410
418
425
426
430
413
0
400
394
395
559
565
635
672
862
983
1,058
1,211
1,394
1,471
1,637
1,805
1,865
2,008
2,345
2,832
3,364
3,788
4,166
4,299
4,483
6,167
6,268
6,331
6,481
6,697
7,311
7,480
7,497
7,844
21,108
22,316
25,220
27,418
29,559
29,889
29,472
29,298
28,801
28,314
27,558
27,55828,31428,80129,29829,47229,88929,55927,41825,22022,31621,1087,8447,4977,4807,3116,6976,4816,3316,2686,1674,4834,2994,1663,7883,3642,8322,3452,0081,8651,8051,6371,4711,3941,2111,058983862672635565559395394400041343042642541841040541228127827402862993210349378390043648453154755460913141320100
       Property Plant Equipment 
20
20
20
13
14
13
429
366
304
279
233
187
144
144
100
75
52
52
39
29
19
19
14
13
144
138
139
145
155
148
142
135
146
146
143
144
144
155
172
191
246
330
403
480
557
569
600
624
569
588
725
1,033
1,403
1,608
1,770
1,677
1,730
3,256
3,189
3,086
2,996
2,964
3,185
3,210
3,149
3,329
16,322
17,451
18,574
21,046
23,201
23,506
23,347
23,165
22,835
22,478
22,115
22,11522,47822,83523,16523,34723,50623,20121,04618,57417,45116,3223,3293,1493,2103,1852,9642,9963,0863,1893,2561,7301,6771,7701,6081,4031,033725588569624600569557480403330246191172155144144143146146135142148155145139138144131419192939525275100144144187233279304366429131413202020
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
192
0
0
0
203
0
0
0
199
0
0
0
211
0
0
0
270
0
0
0
207
0
0
0
360
0
0
0
558
0
0
0
772
0
0
0
1,191
0
0
0
1,838
0
0
0
2,625
0
0
0
3,361
0
0
0
4,222
0
0
0
0
0
0
0
0
0
0
0
0
0000000000004,2220003,3610002,6250001,8380001,191000772000558000360000207000270000211000199000203000192000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
123
0
0
0
126
0
0
0
0
0
0
0
0
0
0
0
0
000000000000126000123000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
192
192
0
0
203
203
0
0
199
199
0
0
211
211
0
0
270
270
0
0
207
207
0
0
360
360
0
0
558
558
0
0
772
772
0
0
1,191
1,191
0
0
1,838
1,838
0
0
2,625
2,625
0
0
3,361
3,361
0
0
4,222
4,222
0
0
4,702
0
0
0
4,391
0
0
0
3,907
3,9070004,3910004,702004,2224,222003,3613,361002,6252,625001,8381,838001,1911,191007727720055855800360360002072070027027000211211001991990020320300192192000000000000
       Long-term Assets Other 
0
-10
0
0
0
0
180
188
243
252
251
249
54
54
279
274
67
67
261
258
56
56
264
268
56
266
271
274
0
277
287
278
47
258
251
251
54
410
463
481
58
652
655
731
65
902
1,037
1,181
105
1,420
1,620
1,800
123
2,180
2,396
2,622
2,753
2,911
3,080
3,245
3,485
3,733
4,126
4,270
5,377
4,515
4,786
4,865
1,944
6,372
4,670
4,695
1,734
4,446
4,278
4,149
-3,654
-3,6544,1494,2784,4461,7344,6954,6706,3721,9444,8654,7864,5155,3774,2704,1263,7333,4853,2453,0802,9112,7532,6222,3962,1801231,8001,6201,4201051,1811,037902657316556525848146341054251251258472782872770274271266562682645656258261676727427954542492512522431881800000-100
> Total Liabilities 
10
70
90
94
102
110
3,685
2,397
1,082
1,435
1,531
872
907
907
1,227
983
1,028
1,028
920
916
971
971
1,224
2,038
2,297
1,724
1,945
1,813
1,804
2,249
2,304
2,076
14,965
14,965
16,166
17,649
18,311
19,652
20,487
20,424
4,505
6,198
2,528
3,447
3,044
3,248
8,814
9,479
10,168
9,860
14,171
12,745
13,840
13,856
13,385
14,179
15,813
15,980
16,940
21,948
23,964
22,912
24,936
24,049
10,735
10,220
23,808
24,456
26,941
27,844
23,646
23,128
27,857
28,508
28,350
29,063
29,985
29,98529,06328,35028,50827,85723,12823,64627,84426,94124,45623,80810,22010,73524,04924,93622,91223,96421,94816,94015,98015,81314,17913,38513,85613,84012,74514,1719,86010,1689,4798,8143,2483,0443,4472,5286,1984,50520,42420,48719,65218,31117,64916,16614,96514,9652,0762,3042,2491,8041,8131,9451,7242,2972,0381,2249719719169201,0281,0289831,2279079078721,5311,4351,0822,3973,68511010294907010
   > Total Current Liabilities 
10
60
80
84
92
100
3,685
2,397
1,082
1,435
1,531
872
907
907
1,177
933
978
978
920
916
971
971
1,224
2,038
1,219
1,230
1,419
1,589
1,528
2,249
2,304
2,076
2,077
2,077
2,104
3,066
3,065
3,299
2,769
1,549
4,505
6,198
2,528
3,447
3,044
3,248
3,933
4,999
6,090
6,183
6,230
5,778
7,848
3,986
3,491
4,261
6,538
6,711
6,919
9,302
9,936
11,464
15,664
17,357
10,153
9,759
10,796
11,070
13,690
14,672
10,554
10,119
9,715
10,436
10,351
11,972
14,546
14,54611,97210,35110,4369,71510,11910,55414,67213,69011,07010,7969,75910,15317,35715,66411,4649,9369,3026,9196,7116,5384,2613,4913,9867,8485,7786,2306,1836,0904,9993,9333,2483,0443,4472,5286,1984,5051,5492,7693,2993,0653,0662,1042,0772,0772,0762,3042,2491,5281,5891,4191,2301,2192,0381,2249719719169209789789331,1779079078721,5311,4351,0822,3973,6851009284806010
       Short-term Debt 
10
50
50
56
56
58
1,000
1,000
0
0
0
0
0
0
0
0
0
50
50
0
0
173
173
872
0
0
0
238
294
1,147
1,185
973
926
926
912
1,562
1,644
1,727
709
445
763
0
0
0
656
417
417
417
833
1,250
2,000
3,000
4,000
4,000
9,894
0
667
2,056
1,233
3,539
2,095
4,610
7,084
9,600
447
463
252
266
571
487
417
377
109
112
114
950
2,874
2,8749501141121093774174875712662524634479,6007,0844,6102,0953,5391,2332,05666709,8944,0004,0003,0002,0001,2508334174174176560007634457091,7271,6441,5629129269269731,1851,1472942380008721731730050500000000001,0001,000585656505010
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
833
0
0
0
833
417
417
417
833
1,250
9,941
3,000
4,000
9,870
9,894
0
667
1,667
833
3,125
1,667
4,167
6,667
9,167
0
0
0
0
0
0
0
0
0
0
0
833
2,500
2,500833000000000009,1676,6674,1671,6673,1258331,66766709,8949,8704,0003,0009,9411,2508334174174178330008330000000000000000000000000000000000000000
       Accounts payable 
0
0
32
32
36
43
2,281
1,259
942
879
808
706
0
775
1,116
861
0
885
822
806
852
852
820
828
818
767
833
784
675
648
621
728
801
801
721
572
787
528
526
446
698
475
418
527
685
861
1,022
740
1,330
1,660
1,581
1,288
1,567
2,140
1,253
1,859
1,966
1,841
2,150
2,072
2,668
1,770
2,727
2,386
2,467
1,678
2,166
3,358
2,805
4,826
2,129
2,348
2,506
2,995
2,836
3,442
3,802
3,8023,4422,8362,9952,5062,3482,1294,8262,8053,3582,1661,6782,4672,3862,7271,7702,6682,0722,1501,8411,9661,8591,2532,1401,5671,2881,5811,6601,3307401,02286168552741847569844652652878757272180180172862164867578483376781882882085285280682288508611,11677507068088799421,2592,2814336323200
       Other Current Liabilities 
0
10
30
52
0
0
404
139
140
556
723
166
0
132
60
71
0
92
48
110
119
119
232
338
401
463
586
566
558
454
498
374
350
350
471
496
362
927
1,528
655
3,013
5,723
2,110
2,920
1,673
2,388
2,912
2,303
1,856
1,665
1,046
1,490
2,267
1,847
2,238
2,402
3,906
389
3,536
3,691
5,015
5,084
5,853
5,371
6,205
7,619
8,378
7,447
8,153
9,359
5,896
5,672
5,417
5,712
5,819
7,580
6,489
6,4897,5805,8195,7125,4175,6725,8969,3598,1537,4478,3787,6196,2055,3715,8535,0845,0153,6913,5363893,9062,4022,2381,8472,2671,4901,0461,6651,8562,3032,9122,3881,6732,9202,1105,7233,0136551,5289273624964713503503744984545585665864634013382321191191104892071601320166723556140139404005230100
   > Long-term Liabilities 
0
10
10
10
10
10
3,281
2,259
942
879
808
706
0
775
50
50
0
50
872
806
0
852
993
1,700
1,077
494
527
225
276
1,795
1,806
1,701
0
12,888
14,062
14,584
15,246
16,353
17,718
18,874
729
475
418
527
715
861
4,881
4,480
4,078
3,677
7,941
6,966
5,992
9,870
9,894
9,917
9,275
9,268
10,021
12,646
14,028
11,448
9,272
6,692
582
461
13,012
13,386
13,251
13,172
13,092
13,009
18,142
18,072
17,999
17,091
15,440
15,44017,09117,99918,07218,14213,00913,09213,17213,25113,38613,0124615826,6929,27211,44814,02812,64610,0219,2689,2759,9179,8949,8705,9926,9667,9413,6774,0784,4804,88186171552741847572918,87417,71816,35315,24614,58414,06212,88801,7011,8061,7952762255274941,0771,7009938520806872500505077507068088799422,2593,28110101010100
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
527
225
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,881
0
0
0
0
0
0
0
9,894
9,917
9,275
8,298
9,155
11,891
13,386
10,921
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000010,92113,38611,8919,1558,2989,2759,9179,89400000004,88100000000000000000022552700000000000000000000000000
> Total Stockholder Equity
0
-40
-60
-74
-83
-94
1,892
1,775
2,363
1,319
488
453
0
-104
2,919
2,896
0
2,359
870
372
1,267
1,268
-271
-928
-485
1,151
1,917
1,121
318
535
592
1,192
1,262
-11,625
-13,185
-13,610
-14,266
-7,259
-9,230
-10,797
3,963
9,666
11,571
9,355
8,211
6,264
3,897
1,379
-474
-1,571
7,916
9,474
10,263
14,447
21,561
20,071
16,935
15,015
11,543
6,734
3,418
21,314
24,322
80,233
79,216
77,259
74,385
70,611
62,578
55,428
47,560
39,142
35,375
28,955
24,095
18,512
23,275
23,27518,51224,09528,95535,37539,14247,56055,42862,57870,61174,38577,25979,21680,23324,32221,3143,4186,73411,54315,01516,93520,07121,56114,44710,2639,4747,916-1,571-4741,3793,8976,2648,2119,35511,5719,6663,963-10,797-9,230-7,259-14,266-13,610-13,185-11,6251,2621,1925925353181,1211,9171,151-485-928-2711,2681,2673728702,35902,8962,919-10404534881,3192,3631,7751,892-94-83-74-60-400
   Common Stock
0
10
10
8
8
8
24
24
25
25
25
25
0
25
25
25
0
25
42
48
66
66
102
111
123
140
166
172
178
190
199
210
215
215
234
245
251
299
310
323
23
25
25
25
25
25
25
25
25
26
28
28
29
30
31
32
32
32
32
32
33
36
37
43
43
43
43
43
43
44
44
44
44
44
44
44
54
5444444444444444434343434343373633323232323231302928282625252525252525252332331029925124523421521521019919017817216614012311110266664842250252525025252525242488810100
   Retained Earnings -282,505-276,670-267,477-261,324-253,998-253,232-241,031-230,152-221,185-211,878-205,472-200,794-196,627-195,949-195,109-192,242-188,789-184,840-177,955-174,408-169,524-164,121-161,116-155,295-152,313-149,166-146,959-145,843-144,465-140,050-137,367-134,362-132,526-130,524-127,677-129,111-124,394-113,903-111,123-107,895-105,806-104,469-102,979-98,732-98,732-97,554-96,273-94,648-92,558-90,628-88,164-85,945-83,989-82,933-81,743-78,903-78,903-78,429-77,413-75,461-75,461-74,638-73,621-71,538-71,538-70,743-69,963-69,060-67,427-66,229-65,185-199-188-180-170-150-133
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
89,914
91,575
0
0
0
0
0
88,795
89,574
90,588
91,343
100,391
101,632
102,714
0
138,180
0
0
140,127
140,262
140,755
140,981
143,066
143,479
154,690
158,734
162,907
170,403
182,674
184,090
186,138
188,796
189,121
190,385
191,649
212,384
218,864
276,656
277,533
278,586
280,654
282,479
283,194
284,048
285,005
286,129
287,000
288,514
290,199
0
0
00290,199288,514287,000286,129285,005284,048283,194282,479280,654278,586277,533276,656218,864212,384191,649190,385189,121188,796186,138184,090182,674170,403162,907158,734154,690143,479143,066140,981140,755140,262140,12700138,1800102,714101,632100,39191,34390,58889,57488,7950000091,57589,91400000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
133
100
110
97
97
97
67,048
67,973
69,758
72,347
72,418
73,163
0
73,581
78,686
79,680
0
80,059
78,233
78,745
0
82,409
81,364
81,888
85,692
86,951
89,914
91,575
95,037
94,992
96,664
98,535
0
86,903
89,574
90,588
91,343
100,391
101,632
102,714
128,106
138,180
138,727
139,409
140,127
140,262
140,755
140,981
143,066
143,479
154,690
158,734
162,907
170,403
182,674
184,090
186,138
188,796
189,121
190,385
191,649
212,384
218,864
276,656
277,533
278,586
280,654
282,479
283,194
284,048
285,005
286,129
287,000
288,514
290,199
292,154
305,197
305,197292,154290,199288,514287,000286,129285,005284,048283,194282,479280,654278,586277,533276,656218,864212,384191,649190,385189,121188,796186,138184,090182,674170,403162,907158,734154,690143,479143,066140,981140,755140,262140,127139,409138,727138,180128,106102,714101,632100,39191,34390,58889,57486,903098,53596,66494,99295,03791,57589,91486,95185,69281,88881,36482,409078,74578,23380,059079,68078,68673,581073,16372,41872,34769,75867,97367,048979797110100133



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue36,349
Cost of Revenue-13,957
Gross Profit22,39222,392
 
Operating Income (+$)
Gross Profit22,392
Operating Expense-52,945
Operating Income-30,553-30,553
 
Operating Expense (+$)
Research Development15,729
Selling General Administrative37,872
Selling And Marketing Expenses-4,272
Operating Expense52,94549,329
 
Net Interest Income (+$)
Interest Income0
Interest Expense-158
Other Finance Cost-0
Net Interest Income-158
 
Pretax Income (+$)
Operating Income-30,553
Net Interest Income-158
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-29,321-31,785
EBIT - interestExpense = -30,711
-29,321
-28,350
Interest Expense158
Earnings Before Interest and Taxes (EBIT)-30,553-29,163
Earnings Before Interest and Taxes (EBITDA)-28,526
 
After tax Income (+$)
Income Before Tax-29,321
Tax Provision--814
Net Income From Continuing Ops-28,507-28,507
Net Income-28,507
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses66,903
Total Other Income/Expenses Net1,232158
 

Technical Analysis of Cytosorbents
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cytosorbents. The general trend of Cytosorbents is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cytosorbents's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cytosorbents Crp.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.02 < 1.04 < 1.05.

The bearish price targets are: 0.86 > 0.86 > 0.86.

Tweet this
Cytosorbents Crp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cytosorbents Crp. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cytosorbents Crp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cytosorbents Crp. The current macd is -0.01562749.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytosorbents price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cytosorbents. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cytosorbents price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cytosorbents Crp Daily Moving Average Convergence/Divergence (MACD) ChartCytosorbents Crp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cytosorbents Crp. The current adx is 15.41.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cytosorbents shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Cytosorbents Crp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cytosorbents Crp. The current sar is 1.0169.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cytosorbents Crp Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cytosorbents Crp. The current rsi is 40.83. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Cytosorbents Crp Daily Relative Strength Index (RSI) ChartCytosorbents Crp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cytosorbents Crp. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytosorbents price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Cytosorbents Crp Daily Stochastic Oscillator ChartCytosorbents Crp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cytosorbents Crp. The current cci is -100.18473401.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Cytosorbents Crp Daily Commodity Channel Index (CCI) ChartCytosorbents Crp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cytosorbents Crp. The current cmo is -24.99048235.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cytosorbents Crp Daily Chande Momentum Oscillator (CMO) ChartCytosorbents Crp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cytosorbents Crp. The current willr is -92.06730769.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Cytosorbents Crp Daily Williams %R ChartCytosorbents Crp Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cytosorbents Crp.

Cytosorbents Crp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cytosorbents Crp. The current atr is 0.06947422.

Cytosorbents Crp Daily Average True Range (ATR) ChartCytosorbents Crp Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cytosorbents Crp. The current obv is -7,585,755.

Cytosorbents Crp Daily On-Balance Volume (OBV) ChartCytosorbents Crp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cytosorbents Crp. The current mfi is 59.33.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Cytosorbents Crp Daily Money Flow Index (MFI) ChartCytosorbents Crp Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cytosorbents Crp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-29BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Cytosorbents Crp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cytosorbents Crp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.830
Ma 20Greater thanMa 500.923
Ma 50Greater thanMa 1000.965
Ma 100Greater thanMa 2001.097
OpenGreater thanClose0.880
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cytosorbents with someone you think should read this too:
  • Are you bullish or bearish on Cytosorbents? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cytosorbents? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cytosorbents Crp

I send you an email if I find something interesting about Cytosorbents Crp.


Comments

How you think about this?

Leave a comment

Stay informed about Cytosorbents Crp.

Receive notifications about Cytosorbents Crp in your mailbox!